ClinicalTrials.gg
RecruitingNCT07724587Updated Jul 24, 2026

The Effectiveness and Safety of Combined Research on Uremic Sarcopenia

An interventional study of Received mindfulness meditation training during dialysis in addition to exercise therapy. in Sarcopenia, sponsored by Ningbo Medical Center Lihuili Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Ningbo Medical Center Lihuili Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Sep 2025, registered Apr 2026).
  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Sarcopenia with a site in China — 47 open to participants now, 52 under way, 4 of them phase 3. Sarcopenia · China.

Planned enrollment
36th of 52
76 · median 110
Started
2025
with 10 others
No phase
42 of 83
20 open now
Primary completion
2026-12
later than 21 of 51 live
Registered
68th of 83
by date

Among the 83 studies in Sarcopenia with a site in China, this one is the 36th largest by planned enrollment of the 52 interventional ones that give a count, is one of 11 that started in 2025, is one of 42 with no phase, reaches primary completion later than 21 of the 51 other live ones, and was the 68th registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

47 of the 83 studies in Sarcopenia with a site in China are open now. Recruiting first, the newest first:

41 more — sign in →

All 47 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Sarcopenia with a site in China, or all of them as a file.
02

Study summary

Objective: To investigate the clinical efficacy and safety of mindfulness meditation during dialysis combined with pre-dialysis progressive resistance training (PRT) for sarcopenia in patients undergoing maintenance hemodialysis (MHD).

Methods: In the randomized controlled trial, 76 MHD patients with sarcopenia were divided into three groups: control group (CG), sports group (SG), and intervention group (IG). All groups received standard dialysis, health education, and dietary guidance. The SG received pre-dialysis PRT, while the IG added mindfulness meditation during dialysis. Efficacy and safety were evaluated at baseline and after 12 weeks. Ultrasound assessments of muscle mass were conducted at baseline, week 4, week 8, and week 12.

Read the detailed description

Control Group: Received routine hemodialysis treatment. Sports Group: Received pre-dialysis resistance training in addition to routine treatment.

Combined Intervention Group: Received mindfulness meditation training during dialysis in addition to exercise therapy.

The study was designed as a single-blind trial. The outcome assessors were blinded to group allocation to reduce assessment bias, particularly in the evaluation of subjective measures such as sleep quality, anxiety, and depression.

Interventions and Methods: Including 4 parts: Part 1 comprehensive assessment and preliminary education; Part 2 testing of one repetition maximum (1RM); Part 3 pre-dialysis resistance training; Part 4 mindfulness meditation training during dialysis.

Comprehensive Assessment and Preliminary Education: Collection of general information (including gender, age, dialysis age, primary disease, etc.). Health education, dietary guidance (calorie intake 30-35kj/kg/d; protein intake 1.0-1.2g/kg/d; maintain weight gain during dialysis within 3%-5% of dry weight). Establishment of a joint intervention team (including 2 meditation instructors, 1 rehabilitation therapist, 2 specialists, and 2 nurses). One week before the trial, patients were introduced to the theoretical knowledge, specific methods, and precautions of mindfulness meditation and PRT training. According to the "Expert Consensus on Exercise Rehabilitation for Chinese Adult Patients with Chronic Kidney Disease" , all participants had no serious complications or comorbidities and were all medium-low risk patients who could undergo incremental moderate-high intensity RT (1 RM 70-85% exercise load).

1RM Assessment: First, perform 5-10 minutes of warm-up exercises for the relevant muscle groups. Choose a weight close to the individual's maximum effort to overcome and begin testing, requiring the completion of 2 squatting movements. Gradually increase the barbell weight in the order of 5kg, 2kg, and 1kg until only one squat can be completed. This weight is recorded as 1RM. Rest for 2-3 minutes between each squat attempt.

Resistance Training: Patients underwent resistance training in the hemodialysis center's gym under the guidance of a rehabilitation therapist 1-2 hours before each dialysis session. The RT prescription was formulated with reference to "the American College of Sports Medicine, ACSM Guidelines for Exercise Testing and Prescription (9th Edition)" and the 2020 KDIGO Clinical Practice Guidelines to develop individualized exercise programs . The control group received routine dialysis treatment.

Mindfulness Meditation Training: After starting dialysis and once blood pressure and heart rate stabilized (approximately 10 minutes), MHD patients were intervened upon using mindfulness hemodialysis meditation audio developed by Lihuili Hospital [20].

Observation Indicators and Methods:

Exercise Capacity: CS-30, HGS, 6MWT, 22StairsUpDownTime, TT10SU. The 30-second chair stand test was used to assess lower limb muscle strength in the "sit-to-stand" state before and after 12 weeks of intervention. Patients crossed their arms over their chest and then performed rapid, continuous "stand up, sit down" movements for a limited time of 30 seconds. The fewer the number of movements within 30 seconds, the worse the lower limb muscle strength. HGS: Measured 3 times using a T.K.K 5001GRIP-A grip strength meter (HKBG., Ltd, Sweden), and the average value was taken. 6MWT, time to climb up and down 22 stairs, and time to stand up and sit down 10 times were measured before and after 12 weeks of intervention. 6MWT: Performed according to the method reported by A.T.S . Subjects walked back and forth in a quiet and ventilated dialysis room corridor with a length of 30m, and the final 6MWT was measured. Time to climb up and down 22 stairs: Subjects continuously climbed up and down 22 stairs (vertical height of approximately 3.3m) and the time taken was recorded. Time to stand up and sit down 10 times: Subjects repeatedly stood up and sat down from a standard-height chair, and the time taken to stand up and sit down 10 times was recorded, and the average value was taken.

Dynamic Balance Function (Timed Up and Go Test, TUGT): The "stand-up and walk" test was used. After the "start" command was issued, the subject stood up from a seated position (on a chair with a backrest), then walked forward 3m as quickly as possible, then turned 180° around the 3m marker and quickly walked back to the chair and sat down with their back against the backrest. The time taken for the entire process was recorded. The longer the time taken, the worse the patient's dynamic balance function .

Ultrasound Examination of the Quadriceps Femoris : The patient was placed in a supine position with the upper body elevated 30°, and both legs were kept relaxed and straight while avoiding internal and external rotation of the hip and knee joints. The linear array probe was placed vertically at approximately the lower 1/3 of the line connecting the anterior superior iliac spine and the upper edge of the patella, keeping the sound beam perpendicular to the femoral body and the probe pointing dorsally. The probe position was adjusted to examine each muscle of the quadriceps femoris (including the cross-sectional area of the rectus femoris, the thickness of the rectus femoris, and the thickness of the vastus intermedius) on the right thigh. The values of each parameter of the quadriceps femoris on the right thigh were measured three times at W0, W4, W8, and W12, and the average value was taken.

5.4 Sleep, Anxiety, and Depression Scores: The Pittsburgh Sleep Quality Index (PSQI) , Self-Rating Anxiety Scale (SAS), and Self-Rating Depression Scale (SDS) were used for evaluation .

The psychometric properties (validity and reliability) of these scales have been validated in populations similar to the study cohort, as referenced in previous literature. Assessors were trained and underwent consistency checks to ensure reliable application of these scales.

Laboratory Tests (Inflammatory Markers, Nutritional Markers, and Dialysis Adequacy): Fasting elbow venous blood was collected to measure interleukin-6 (IL-6), high-sensitivity C-reactive protein (Hs-CRP), tumor necrosis factor (TNF), albumin (ALB), prealbumin (PA), adequacy index (KT/V), etc., before and after the intervention.

Comparison of the occurrence of adverse reactions: Adverse events were monitored throughout the study. These included physical injuries from exercise, as well as psychological distress related to the mindfulness meditation intervention. Adverse events were classified according to their severity and managed appropriately. A report and monitoring mechanism was established for any serious adverse events.

03

Conditions studied

  • Sarcopenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet the updated Asian diagnostic criteria for sarcopenia
  • Stable vital signs and general physical condition
  • Willing and able to cooperate with supervised exercise training
  • Regular hemodialysis 3 times per week for at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Acute cardiovascular or cerebrovascular events within the previous 3 months
  • Cognitive dysfunction affecting study cooperation and exercise completion
  • Severe osteoarticular or limb movement disorders preventing standardized exercise training
  • Active systemic infection
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
76 participants (estimated)

Study arms

  • Other
    control group (CG)

    Received routine hemodialysis treatment

    Behavioral: Received mindfulness meditation training during dialysis in addition to exercise therapy.

  • Active comparator
    sports group (SG)

    Received pre-dialysis resistance training in addition to routine treatment.

    Behavioral: Received mindfulness meditation training during dialysis in addition to exercise therapy.

  • Experimental
    intervention group (IG)

    Received mindfulness meditation training during dialysis in addition to exercise therapy.

    Behavioral: Received mindfulness meditation training during dialysis in addition to exercise therapy.

Interventions

  • BehavioralReceived mindfulness meditation training during dialysis in addition to exercise therapy.

    The SG received pre-dialysis progressive resistance training (PRT), while the IG added mindfulness meditation during dialysis.

06

What researchers measure

Primary outcomes

  1. Change in 30-second Chair Stand Test (CS30)

    The range of the test result is 0-30 repetitions. Higher values indicate better lower limb muscle strength and physical function. The change value before and after 12-week intervention is the evaluation index

    Time frame: 12 weeks

  2. Change in Handgrip Strength

    The unit of handgrip strength is kg. Higher values indicate improved upper limb muscle strength. The change value before and after 12-week intervention is the evaluation index

    Time frame: 12 weeks

  3. Change in 6-Minute Walking Test (6MWT)

    The unit of walking distance is meters. Longer walking distance indicates better exercise tolerance and physical endurance. The change value before and after 12-week intervention is the evaluation index.

    Time frame: 12 weeks

  4. Change in Stair Climbing Test

    The unit of test result is seconds. Shorter completion time indicates improved lower limb motor function. The change value before and after 12-week intervention is the evaluation index.

    Time frame: 12 weeks

  5. Change in 10-Time Sit-to-Stand Test (TT10SU)

    The unit of test result is seconds. Shorter completion time indicates better lower limb muscle function. The change value before and after 12-week intervention is the evaluation index.

    Time frame: 12 weeks

  6. Change in Timed Up and Go Test (TUGT)

    The unit of test result is seconds. Shorter completion time indicates better balance and mobility function. The change value before and after 12-week intervention is the evaluation index.

    Time frame: 12 weeks

  7. Change in skeletal muscle thickness measured by ultrasound

    The unit of skeletal muscle thickness is cm. Greater muscle thickness indicates improved muscle mass. The change value before and after 12-week intervention is the evaluation index.

    Time frame: 4 weeks

  8. Change in quality of life assessed by standardized scale

    Higher scores of the standardized quality of life scale represent improved quality of life and physical performance. The change value before and after 12-week intervention is the evaluation index.

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Yongyao Wu
    Ningbo, 315100, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 15 months is below that.

Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
Jul 24, 2026
StartActual
Sep 1, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07724587
Lead sponsor
Ningbo Medical Center Lihuili Hospital
Responsible party
Sponsor
First posted
Jul 24, 2026
Start date
Sep 1, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Jul 24, 2026

Study contacts

yongyao wu
Contact
wuyongyao.12345@163.com
8615967857855
yongyao wu
principal investigator · Department of Nephrology, Ningbo Medical Center Li Huili Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion